FRAXA Accelerates Progress toward a Cure for Fragile X Syndrome
Our Mission
To find effective treatments and ultimately a cure for Fragile X syndrome.
We directly fund research grants and fellowships at top universities around the world. We partner with biomedical and pharmaceutical companies, large and small, to bridge the gap between research discoveries and actual treatments.
Treatments for Fragile X are likely to help people affected by autism, Alzheimer’s, and other brain disorders.
FRAXA Research Foundation in the News
NPR Spotlights Zatolmilast: A Potential Breakthrough for Fragile X Syndrome
NPR spotlights zatolmilast, a promising investigational drug to treat Fragile X syndrome. Families report life-changing improvements in learning and independence.
Forbes, “Clinical Trials Expand For AI-Designed Drug To Treat Fragile X Syndrome”
British startup Healx has secured FDA approval for a phase 2a clinical trial of an AI-discovered compound that could help manage the symptoms of the genetic disorder Fragile X syndrome. The start of the trial marks another milestone in the use of artificial intelligence to help find new applications for existing drugs by mining patient records and research databases.
USA Today, “Fragile X treatment: Decades later, progress in rare genetic condition”
USA Today profiled FRAXA co-founders Mike Tranfaglia, Katie Clapp, and their son Andy, highlighting how science is transforming rare disease care.
Give with Confidence
An investment in FRAXA is an investment in the future of those living with Fragile X. Become a partner in our life-changing work by donating to FRAXA today.
FRAXA recognizes the responsibility that comes with your contribution and is proud to be continually recognized as one of the most reliable stewards of donor gifts. We earn the highest marks possible from major nonprofit rating agencies. All our staff and board members are parents whose children live with Fragile X syndrome.
Research Funding Per Year
FRAXA’s mission is to find effective treatments and ultimately a cure for Fragile X syndrome. We directly fund research grants and fellowships at top universities around the world and prioritize the funding of Fragile X clinical trials.
Charity Navigator is the largest charity evaluator in America. Its website helps guide intelligent giving by evaluating the Financial Health and Accountability & Transparency of an organization. Their ratings show donors how efficiently a charity will use their support, how well it has sustained its programs and services over time, and their level of commitment to accountability and transparency. FRAXA Research Foundation is ranked a four-star charity by Charity Navigator.
GreatNonprofits is the leading platform for community-sourced stories about nonprofits. Through the collection of donor, community and volunteer stories, GreatNonprofits inspires giving by amplifying the voices of loyal supporters.
FRAXA is proud to be a Top-Rated nonprofit by GreatNonprofits. FRAXA has earned top-rated status every year.
Candid, formerly Guidestar, utilizes factual information from a nonprofit’s financial statements, board governance model and communication strategy to assess their level of transparency. They partner with industry leaders to help donors make decisions with confidence. FRAXA earned Platinum Seal of Transparency, the highest possible, from Candid.